Decision Diagnostics Corp. (DECN) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerDecision Diagnostics Corp. (DECN) trades at $0.0001. Decision Diagnostics Corp. (DECN) is a healthcare company focused on developing smartphone-based electronic medical record technologies and home-use diagnostic solutions. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for DECN: DECN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Decision Diagnostics Corp. (DECN) Healthcare & Pipeline Overview
Decision Diagnostics Corp. (DECN) specializes in smartphone-based electronic medical record technologies and glucose monitoring solutions, catering to both human and veterinary markets, with a focus on innovative home-use diagnostic products.
What Is the Investment Thesis for DECN?
Decision Diagnostics Corp. (DECN) operates in a niche market characterized by a growing demand for mobile health solutions and home diagnostics. The company's focus on glucose monitoring products positions it well within the expanding diabetes care market, projected to reach $32 billion by 2027. DECN's proprietary products, such as the GenUltimate! glucose test strips and the GenUltimate! 4Pets system, provide unique offerings that cater to both human and veterinary health, potentially driving revenue growth. The company's ongoing efforts to acquire and maintain intellectual property could further enhance its competitive edge. However, the significant negative profit margin of -1499.1% indicates that the company is currently facing financial challenges, which could impact its ability to invest in growth initiatives. As the healthcare sector increasingly shifts towards mobile solutions, DECN's innovations may capture market share, but the company must navigate regulatory hurdles and market competition effectively.
Based on FMP financials and quantitative analysis
DECN Key Highlights
Market Cap: $0.00B, indicating a current valuation challenge.
- Profit Margin: -1499.1%, reflecting ongoing financial difficulties.
- Gross Margin: 25.2%, indicating some profitability in product sales.
- Beta: -0.05, suggesting low volatility compared to the market.
- No dividend yield, indicating a focus on reinvestment rather than shareholder returns.
Who Are DECN's Competitors?
DECN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| LGND Ligand Pharmaceuticals Incorporated | $306.77 | +1.26% | $6.15B | 96 5-pillar |
| POM Pomdoctor Limited | $0.93 | +8.13% | $6.30M | 34 5-pillar |
| MEDS TRxADE HEALTH, Inc. | $3.35 | -8.97% | $8.79M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.05 | -5.29% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.45 | -0.58% | $18.7M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.82 | +3.03% | $23.1M | — |
| KYNB Kyntra Bio, Inc. | $6.09 | -3.49% | $24.7M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DECN's Key Strengths?
Innovative product offerings in glucose monitoring.
- Strong intellectual property portfolio.
- Expertise in mobile health technologies.
- Diverse revenue streams from both human and veterinary markets.
What Are DECN's Weaknesses?
Significant negative profit margin indicating financial challenges.
- Small team size may limit operational capacity.
- Limited brand recognition compared to larger competitors.
- Dependence on a niche market may restrict growth potential.
What Are the Key Risks for DECN?
Financial-distress signal — its Altman Z-Score of -22.72 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles could delay product launches and market entry.
- Financial instability indicated by a negative profit margin may limit growth.
- Increased competition from larger pharmaceutical companies may impact market share.
- Dependence on a niche market may restrict revenue growth opportunities.
What Threats Does DECN Face?
- Intense competition from larger healthcare companies.
- Regulatory hurdles in the healthcare industry.
- Market volatility affecting funding and investment.
- Rapid technological advancements requiring continuous innovation.
What Are DECN's Competitive Advantages?
- Unique product offerings in glucose monitoring for both humans and pets.
- Strong portfolio of intellectual property, including patents and trademarks.
- Focus on mobile-centric solutions that align with current healthcare trends.
- Established relationships with healthcare providers and organizations.
- Innovative software solutions that enhance patient care management.
What Does DECN Do?
Founded in 2000 and headquartered in Westlake Village, California, Decision Diagnostics Corp. (DECN) has established itself as a key player in the healthcare sector, particularly in the development of electronic medical record (EMR) technologies optimized for smartphones. Originally known as InstaCare Corp., the company rebranded to Decision Diagnostics in November 2011 to better reflect its focus on diagnostics and healthcare solutions. DECN's product offerings are diverse, including regulated and unregulated diagnostic solutions, home-use testing products for chronic illness management, and direct-to-patient logistics for diabetes programs. A significant portion of their product line revolves around glucose monitoring, featuring the GenUltimate! glucose test strips, which are classified as Class II medical devices for personal at-home use. Additionally, the company caters to the veterinary market with PetSure! glucose test strips designed for dogs and cats, and the proprietary GenUltimate! 4Pets Glucose system for testing glucose levels in various animals. Beyond product development, Decision Diagnostics actively manages a portfolio of intellectual property, including patents and trademarks. Their software solutions, such as MD@Hand, Practice Probe, and ResidenceWare, enhance patient care management and streamline communication in residential management. With a small team of six employees, DECN continues to innovate in the healthcare technology landscape, aiming to provide essential tools for healthcare professionals at the point of care.
What Products and Services Does DECN Offer?
- Develop smartphone-based electronic medical record technologies.
- Manufacture glucose monitoring products for humans and pets.
- Provide home-use testing solutions for chronic illness management.
- Facilitate direct-to-patient logistics for diabetes programs.
- Offer software solutions for healthcare management and data mining.
- Acquire and maintain a portfolio of intellectual property related to healthcare technologies.
How Does DECN Make Money?
- Generate revenue through the sale of glucose monitoring products and test strips.
- Offer software solutions that enhance patient care management for healthcare providers.
- Engage in licensing agreements for proprietary technology and intellectual property.
- Provide fulfillment services for diabetes management programs.
- Capitalize on both regulated and unregulated diagnostic solutions.
What Industry Does DECN Operate In?
The healthcare industry, particularly the medical pharmaceuticals sector, is experiencing significant growth driven by technological advancements and an increasing focus on personalized medicine. The global diabetes care market is expected to expand rapidly, with a projected CAGR of 8.6% from 2020 to 2027. Decision Diagnostics Corp. operates within this dynamic landscape, focusing on mobile health and home diagnostics, which are becoming increasingly important as patients seek convenient and accessible healthcare solutions. The competitive landscape includes major players like Ligand Pharmaceuticals (LGND), which emphasizes the need for DECN to differentiate its offerings and maintain a strong market presence.
Who Are DECN's Key Customers?
- Healthcare providers seeking innovative diagnostic solutions.
- Individuals managing chronic illnesses, particularly diabetes.
- Veterinary clinics and pet owners requiring glucose monitoring for animals.
- Healthcare organizations interested in integrated software solutions.
- Research institutions looking for diagnostic technologies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Decision Diagnostics Corp. operates in the Healthcare sector. It is headquartered in Westlake Village, US. The company is led by CEO Keith Berman. DECN has traded publicly since 2002.
Financial Health
Decision Diagnostics Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -22.72 places it in the distress zone, a signal of elevated financial risk.
DECN Financials
DECN Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
DECN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for DECN.
Price Targets
Wall Street price target analysis for DECN.
DECN MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for DECN; grades run from A+ (80-100) to F (below 30).
Leadership: Keith Berman
CEO
Keith Berman has been at the helm of Decision Diagnostics Corp. since its inception in 2000. With a background in healthcare technology and management, he has played a pivotal role in shaping the company's strategic direction. Under his leadership, DECN has focused on developing innovative diagnostic solutions that cater to both human and veterinary markets.
Track Record: Keith Berman has successfully guided Decision Diagnostics through various phases of product development and market entry, establishing a strong portfolio of glucose monitoring products. His leadership has been instrumental in the company's rebranding and focus on mobile health technologies.
DECN OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers like OTCQX or OTCQB, often resulting in lower visibility and trading volumes. Companies in this tier may have less stringent reporting requirements, which can affect transparency and investor confidence.
- OTC Tier: OTC Other
- Limited financial disclosure may lead to uncertainty regarding the company's performance.
- Lower trading volumes can result in increased volatility and price fluctuations.
- Potential regulatory scrutiny may affect operations and market access.
- Competition from larger, more established companies may hinder growth.
- Verify the company's financial statements and disclosures.
- Assess the competitive landscape and market positioning.
- Examine the regulatory environment affecting the company's products.
- Review the management team's experience and track record.
- Investigate potential partnerships or collaborations.
- Established since 2000, indicating a long history in the industry.
- Diverse product offerings in both human and veterinary markets.
- Active portfolio of intellectual property, including patents.
DECN Healthcare Stock FAQ
What are the main risks for DECN?
Decision Diagnostics Corp. faces several risks, including regulatory hurdles that could impede product launches and market access. The company's significant negative profit margin indicates ongoing financial challenges, which may limit its ability to invest in growth initiatives.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial reporting and transparency due to OTC classification.